Encouraging data on IPH 1101 at the ASCO annual meeting
Total number of shares outstanding and voting rights, as of April 30, 2008
Outcome of the AGM that took place on June 27, 2008
IPH 1101 in combination with rituximab enters the second part of the Phase I/II trial in fNHL
Turnover for the first semester of 2008
Financial results for the first half of 2008
Acquisition of exclusive development and commercial rights to IPH2101 in the context of a swap of products
Presentation at the AASLD Annual Meeting in San Francisco, USA
Turnover of 5.9 million euros for the first nine months of 2008
IPH 4201 enters in pre-clinical validation
